Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations
Condition(s) studied
Investigational drug(s) / intervention(s)
Osimertinib: Single arm treated by osimertinib
Study summary
This is an observational multicenter study. A cross-sectional descriptive study of patients with locally advanced or metastatic Non Small Cell Lung Cancer with activating EGFR mutation treated by any first line therapy will be used to identify cohort with a prospective follow-up of patients initiating a treatment by osimertinib in first line
* A cross-sectional descriptive study of all patients with locally advanced or metastatic NSCLC with activating EGFR mutation treated by any first line therapy will be collected at the study participating sites. The study which is transversal will allow to characterize the population of patients with locally advanced or metastatic NSCLC with activating EGFR mutation treated in first line, the day of first line initiation.
* Additionally, a prospective study targeting a cohort of patients focusing on patients with locally advanced or metastatic NSCLC with activating EGFR mutation initiating a treatment by osimertinib in first line will be conducted to address describe in real life conditions the 36-months overall survival, patients baseline characteristics, disease evolution, sequencing and treatment patterns, and quality of life
Eligibility
Primary outcome measure(s)
- Overall survival — 36 months
36-months overall survival defined as time from index date until death from any cause
Trial sites (46)
| Facility | City | Region | Status |
|---|---|---|---|
| Research Site | Abbeville | France | |
| Research Site | Aix-en-Provence | France | |
| Research Site | Angers | France | |
| Research Site | Antibes | France | |
| Research Site | Avignon | France | |
| Research Site | Bastia | France | |
| Research Site | Bayonne | France | |
| Research Site | Bordeaux | France | |
| Research Site | Bourg-en-Bresse | France | |
| Research Site | Brest | France | |
| Research Site | Cannes | France | |
| Research Site | Chambéry | France | |
| Research Site | Chauny | France | |
| Research Site | Cholet | France | |
| Research Site | Clermont-Ferrand | France | |
| Research Site | Colmar | France | |
| Research Site | Contamine-sur-Arve | France | |
| Research Site | Créteil | France | |
| Research Site | Elbeuf | France | |
| Research Site | Epagny METZ Tessy | France | |
| Research Site | Évreux | France | |
| Research Site | La Roche-sur-Yon | France | |
| Research Site | Libourne | France | |
| Research Site | Limoges | France | |
| Research Site | Lyon | France | |
| Research Site | Marseille | France | |
| Research Site | Meaux | France | |
| Research Site | Mulhouse | France | |
| Research Site | Orléans | France | |
| Research Site | Paris | France | |
| Research Site | Poitiers | France | |
| Research Site | Quimper | France | |
| Research Site | Reims | France | |
| Research Site | Rouen | France | |
| Research Site | Saint-Denis | France | |
| Research Site | Saint-Grégoire | France | |
| Research Site | Saint-Pierre | France | |
| Research Site | Saint-Priest-en-Jarez | France | |
| Research Site | Saint-Quentin | France | |
| Research Site | Toulon | France |
+ 6 more sites — see the full list on the official registry below.
On this site
📄 Tagrisso (osimertinib) drug profile →More AstraZeneca trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05103605 on ClinicalTrials.gov ↗ ← All trials in France